Cardiovascular risk | EULAR modified SCORE‡ | ||||||
---|---|---|---|---|---|---|---|
SCORE* n | n | CACS | Carotid ultrasonography | ||||
CACS >100 n=17 (%) | cIMT>0.90 mm n=14 (%) | Carotid plaques n=69 (%) | cIMT>0.90 mm and/or carotid plaques n=70 (%) | cIMT≤0.90 mm and without carotid plaques n=25 (%) | |||
Low (<1%) | 21 | 21 | 0/21 (0.0) | 0/21 (0.0) | 7/21 (33.3) | 7/21 (33.3) | 14/21 (66.7) |
Moderate (≥1% and <5%) | 63 | 60 | 12/60 (20.0) | 8/60 (13.3) | 51/60 (85.0) | 51/60 (85.0) | 9/60 (15.0) |
High (≥5% and <10%) | 9 | 10 | 4/10 (40.0) | 5/10 (50.0) | 8/10 (80.0) | 9/10 (90.0) | 1/10 (10.0) |
Very high (≥10%) | 2 | 4 | 1/4 (25.0) | 1/4 (25.0) | 3/4 (75.0) | 3/4 (75.0) | 1/4 (25.0) |
High plus very high | 11 | 14 | 5/14 (35.7) | 6/14 (42.8) | 11/14 (78.6) | 12/14 (85.7) | 2/14 (14.3) |
EULAR modified SCORE risk stratification according to the Coronary Artery Calcification Score (CACS) >100, carotid intima-media thickness (cIMT) >0.90 mm and carotid plaques.
*According to SCORE for the general population.23 ,24
†Modified SCORE for rheumatoid arthritis: according to the EULAR recommendations.8
‡Modified SCORE was calculated by the application of a multiplier factor of 1.5 in those patients with two of three criteria: disease duration >10 years, rheumatoid factor and/or anticyclic citrullinated peptide antibody positivity, and presence of extra-articular manifestations.8
EULAR, European League Against Rheumatism; SCORE, Systematic Coronary Risk Evaluation.